UNLABELLED: We measured the whole-body distribution of intravenously injected (11)C-N-propylnorapomorphine ((11)C-NPA), a dopamine agonist PET tracer, in human subjects and determined the resulting absorbed radiation doses. METHODS: Six subjects (3 women, 3 men) were injected with (11)C-NPA (nominal dose, 370 MBq). A total of 9 consecutive whole-body PET scans were obtained for each subject. In addition, time-activity curves for 12 organs were determined, and residence times were computed for each subject. Dosimetry was determined for the various body organs and the whole body. RESULTS: The average NPA whole-body radiation dose was 3.17 x 10(-3) mSv per MBq of injected (11)C-NPA. The organ receiving the highest dose was the gallbladder wall, with an average of 2.81 x 10(-2) mSv.MBq(-1). CONCLUSION: On the basis of averaged dosimetry results, an administration of less than 1,780 MBq (<48 mCi) of (11)C-NPA yields an organ dose of under 50 mSv (5 rem) to all organs.
UNLABELLED: We measured the whole-body distribution of intravenously injected (11)C-N-propylnorapomorphine ((11)C-NPA), a dopamine agonist PET tracer, in human subjects and determined the resulting absorbed radiation doses. METHODS: Six subjects (3 women, 3 men) were injected with (11)C-NPA (nominal dose, 370 MBq). A total of 9 consecutive whole-body PET scans were obtained for each subject. In addition, time-activity curves for 12 organs were determined, and residence times were computed for each subject. Dosimetry was determined for the various body organs and the whole body. RESULTS: The average NPA whole-body radiation dose was 3.17 x 10(-3) mSv per MBq of injected (11)C-NPA. The organ receiving the highest dose was the gallbladder wall, with an average of 2.81 x 10(-2) mSv.MBq(-1). CONCLUSION: On the basis of averaged dosimetry results, an administration of less than 1,780 MBq (<48 mCi) of (11)C-NPA yields an organ dose of under 50 mSv (5 rem) to all organs.
Authors: R V Parsey; M Slifstein; D R Hwang; A Abi-Dargham; N Simpson; O Mawlawi; N N Guo; R Van Heertum; J J Mann; M Laruelle Journal: J Cereb Blood Flow Metab Date: 2000-07 Impact factor: 6.200
Authors: Dah-Ren Hwang; Rajesh Narendran; Yiyun Huang; Mark Slifstein; Peter S Talbot; Yasuhiko Sudo; Bart N Van Berckel; Lawrence S Kegeles; Diana Martinez; Marc Laruelle Journal: J Nucl Med Date: 2004-02 Impact factor: 10.057
Authors: Rajesh Narendran; W Gordon Frankle; N Scott Mason; Charles M Laymon; Brian J Lopresti; Julie C Price; Steve Kendro; Shivangi Vora; Maralee Litschge; James M Mountz; Chester A Mathis Journal: Synapse Date: 2009-07 Impact factor: 2.562
Authors: Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2012-12-09 Impact factor: 3.000
Authors: Sjoerd J Finnema; Vladimir Stepanov; Ryuji Nakao; Anna W Sromek; Tangzhi Zhang; John L Neumeyer; Susan R George; Philip Seeman; Michael G Stabin; Cathrine Jonsson; Lars Farde; Christer Halldin Journal: J Nucl Med Date: 2014-05-01 Impact factor: 10.057
Authors: Christopher J Endres; Jennifer M Coughlin; Kenneth L Gage; Crystal C Watkins; Michael Kassiou; Martin G Pomper Journal: J Nucl Med Date: 2012-01-12 Impact factor: 10.057
Authors: Charles M Laymon; Rajesh Narendran; Neale S Mason; Jonathan P Carney; Brian J Lopresti; Chester A Mathis; James M Mountz; Donald Sashin; W Gordan Frankle Journal: Mol Imaging Biol Date: 2012-02 Impact factor: 3.488
Authors: Jussi Hirvonen; Anne Roivainen; Jere Virta; Semi Helin; Kjell Någren; Juha O Rinne Journal: Eur J Nucl Med Mol Imaging Date: 2009-10-28 Impact factor: 9.236
Authors: Tuula Tolvanen; Timo Yli-Kerttula; Tiina Ujula; Anu Autio; Pertti Lehikoinen; Heikki Minn; Anne Roivainen Journal: Eur J Nucl Med Mol Imaging Date: 2010-01-13 Impact factor: 9.236